DOI：10.16658/ki.1672-4062.2023.19.091达格列净、西格列汀及二甲双胍三联疗法治疗2型糖尿病疗效研究姚矿1，谭嘉睿2，王丽朵21.邵阳市中心医院内分泌科，湖南邵阳422000；2.邵阳学院，湖南邵阳422000[摘要]目的研究达格列净、西格列汀及二甲双胍三联疗法治疗2型糖尿病疗效。
方法选取2022年4月—2023年4月邵阳市中心医院收治的100例2型糖尿病患者为研究对象，用随机数表法将其分为对照组和观察组，各50例。
对照组患者接受二甲双胍单药治疗，观察组患者接受达格列净、西格列汀及二甲双胍三联疗法治疗。
比较两组患者治疗前后的空腹血糖（fasting plasma glucose, FPG）、餐后2 h血糖（2-hour postprandial blood glucose, 2 hPG）、糖化血红蛋白（glycated hemoglobin A1c, HbA1c）、收缩压（systolic blood pressure, SBP）、舒张压（diastolic blood pressure, DBP）及体质指数（body mass index, BMI）等变化水平，同时统计两组患者不良反应发生率。
结果治疗后，观察组患者的HbA1c和FPG水平均明显低于对照组，SBP和BMI均明显低于对照组，差异有统计学意义（P<0.05）。
两组患者DBP和2 hPG比较，差异无统计学意义（P>0.05）。
两组患者不良反应发生率比较，差异无统计学意义（P>0.05）。
结论达格列净、西格列汀及二甲双胍三联疗法治疗2型糖尿病疗效显著，能够有效控制患者血糖水平，改善体质指数，且未增加低血糖发生风险，安全性可靠。
[关键词] 达格列净；西格列汀；二甲双胍；三联疗法；2型糖尿病[中图分类号] R4 [文献标识码] A [文章编号] 1672-4062（2023）10（a）-0091-04Study on the Efficacy of Triple Therapy of Dapagliflozin, Sitagliptin and Metformin in the Treatment of Type 2 Diabetes MellitusYAO Kuang1, TAN Jiarui2, WANG Liduo21.Department of Endocrinology, Shaoyang Central Hospital, Shaoyang, Hunan Province, 422000 China;2.Shaoyang College, Shaoyang, Hunan Province, 422000 China[Abstract] Objective To study the efficacy of triple therapy of dapagliflozin, sitagliptin and metformin in the treat⁃ment of type 2 diabetes mellitus.Methods 100 patients with type 2 diabetes mellitus admitted to Shaoyang Central Hospital from April 2022 to April 2023 were selected as the study objects, and were divided into the control group and the observation group by the randomized numerical table method, with 50 patients in each group. Patients in the control group were treated with metformin monotherapy, and patients in the observation group were treated with triple combination therapy of dapagliflozin, sitagliptin and metformin. Fasting plasma glucose (FPG), 2-hour postprandial glucose (2 hPG), HbA1c, systolic blood pressure (SBP), diastolic blood pressure (DBP), and body mass index (BMI) were compared before and after the treatment of the two groups, and the incidence rates of adverse reactions in the pa⁃tients of the two groups were also counted.Results After treatment, the levels of HbA1c and FPG of patients in the ob⁃servation group were significantly lower than those of the control group, and the SBP and BMI were significantly lower than those of the control group, and the difference was statistically significant (P<0.05). The DBP and 2 hPG values between the two groups were compared, and the difference was not statistically significant (P>0.05). There was no sta⁃tistically significant difference in the incidence of adverse reactions between the two groups of patients (P>0.05).Conclusion Dapagliflozin, sitagliptin and metformin triple therapy for the treatment of type 2 diabetes mellitus has sig⁃nificant efficacy, can effectively control the patient's blood glucose level, improve the body mass index and blood pres⁃sure, and not increase the risk of hypoglycemia, whose safety is reliable.[作者简介]姚矿（1991-），男，硕士，主治医师，研究方向为内分泌内科疾病的诊疗。
